Protective 'switch' in most common blood cancer opens new doors for diagnosis and treatment

MedicalXpress | 四月 20, 2026

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) has uncovered a crucial biological "off switch" in diffuse large B cell lymphoma (DLBCL), the most common and one of the most aggressive forms of blood cancer. The findings reveal that a protein called HDAC7 plays a dual role: it is essential for building a healthy immune system, and when it goes missing in cancer cells, the disease becomes significantly more dangerous. Crucially, the team showed that restoring HDAC7 in cancer cells can slow or even stop tumor growth.